Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Anticoagulation After Str… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Anticoagulation After Stroke in Patients With Atrial Fibrillation: To Bridge or Not With Low-Molecular-Weight Heparin?

Artikel i vetenskaplig tidskrift
Författare R. Altavilla
V. Caso
F. Bandini
G. Agnelli
G. Tsivgoulis
S. Yaghi
K. L. Furie
P. Tadi
C. Becattini
M. Zedde
A. H. Abdul-Rahim
K. R. Lees
A. Alberti
M. Venti
M. Acciarresi
C. D'Amore
M. G. Mosconi
L. A. Cimini
J. Fusaro
P. Bovi
M. Carletti
A. Rigatelli
M. Cappellari
J. Putaala
L. Tomppo
Turgut Tatlisumak
S. Marcheselli
A. Pezzini
L. Poli
A. Padovani
L. Masotti
V. Vannucchi
S. I. Sohn
G. Lorenzini
R. Tassi
F. Guideri
M. Acampa
G. Martini
G. Ntaios
G. Athanasakis
K. Makaritsis
E. Karagkiozi
K. Vadikolias
C. Liantinioti
M. Chondrogianni
N. Mumoli
D. Consoli
F. Galati
S. Sacco
A. Carolei
C. Tiseo
F. Corea
W. Ageno
M. Bellesini
G. Silvestrelli
A. Ciccone
A. Lanari
U. Scoditti
L. Denti
M. Mancuso
M. Maccarrone
L. Ulivi
G. Orlandi
N. Giannini
G. Gialdini
T. Tassinari
M. L. De Lodovici
G. Bono
C. Rueckert
A. Baldi
S. D'Anna
D. Toni
F. Letteri
M. Giuntini
E. M. Lotti
Y. Flomin
A. Pieroni
O. Kargiotis
T. Karapanayiotides
S. Monaco
M. M. Baronello
L. Csiba
L. Szabo
A. Chiti
E. Giorli
M. Del Sette
D. Imberti
D. Zabzuni
B. Doronin
V. Volodina
P. Michel
P. Vanacker
K. Barlinn
L. P. Pallesen
J. Barlinn
D. Deleu
G. Melikyan
F. Ibrahim
N. Akhtar
V. Gourbali
M. Paciaroni
Publicerad i Stroke
Volym 50
Nummer/häfte 8
Sidor 2093-2100
ISSN 0039-2499
Publiceringsår 2019
Publicerad vid Institutionen för neurovetenskap och fysiologi
Sidor 2093-2100
Språk en
Länkar dx.doi.org/10.1161/strokeaha.118.02...
Ämnesord anticoagulants, atrial fibrillation, humans, incidence, secondary prevention, acute ischemic-stroke, hemorrhagic transformation, arterial territories, human brain, leukoaraiosis, metaanalysis, outcomes, risk, Neurosciences & Neurology, Cardiovascular System & Cardiology
Ämneskategorier Neurovetenskaper

Sammanfattning

Background and Purpose- Bridging therapy with low-molecular-weight heparin reportedly leads to a worse outcome for acute cardioembolic stroke patients because of a higher incidence of intracerebral bleeding. However, this practice is common in clinical settings. This observational study aimed to compare (1) the clinical profiles of patients receiving and not receiving bridging therapy, (2) overall group outcomes, and (3) outcomes according to the type of anticoagulant prescribed. Methods- We analyzed data of patients from the prospective RAF and RAF-NOACs studies. The primary outcome was defined as the composite of ischemic stroke, transient ischemic attack, systemic embolism, symptomatic cerebral bleeding, and major extracerebral bleeding observed at 90 days after the acute stroke. Results- Of 1810 patients who initiated oral anticoagulant therapy, 371 (20%) underwent bridging therapy with full-dose low-molecular-weight heparin. Older age and the presence of leukoaraiosis were inversely correlated with the use of bridging therapy. Forty-two bridged patients (11.3%) reached the combined outcome versus 72 (5.0%) of the nonbridged patients (P=0.0001). At multivariable analysis, bridging therapy was associated with the composite end point (odds ratio, 2.3; 95% CI, 1.4-3.7; P<0.0001), as well as ischemic (odds ratio, 2.2; 95% CI, 1.3-3.9; P=0.005) and hemorrhagic (odds ratio, 2.4; 95% CI, 1.2-4.9; P=0.01) end points separately. Conclusions- Our findings suggest that patients receiving low-molecular-weight heparin have a higher risk of early ischemic recurrence and hemorrhagic transformation compared with nonbridged patients.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?